Utility of PCD Diagnostics to Improve Clinical Care

Launched by CONNECTICUT CHILDREN'S MEDICAL CENTER · Jun 2, 2023

Keywords

ClinConnect Summary

**Summary of the Clinical Trial: Utility of PCD Diagnostics to Improve Clinical Care**

This clinical trial is exploring new ways to diagnose a condition called primary ciliary dyskinesia (PCD), which affects the lungs and sinuses. Researchers want to see how well a new, non-invasive test called nasal nitric oxide testing works in real-world settings. This test measures levels of a gas called nitric oxide in the nasal passages. People with PCD usually have low levels of this gas, and the goal of the study is to gather more information to help doctors diagnose PCD more effectively in both children and adults who show signs of the condition.

To participate in this study, individuals need to be at least 2 years old and have a history of certain health issues, such as chronic cough, frequent nasal congestion, or other related symptoms. Participants can expect to undergo a simple nasal test and will be closely monitored throughout the study. It's important to note that those with recent sinus surgery, current infections needing antibiotics, or who cannot tolerate the test may not be eligible. Overall, this study aims to improve how we diagnose and care for patients with primary ciliary dyskinesia, helping them receive better treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 2 years of age
• * Must have two of the following clinical history points:
• • Neonatal respiratory distress
• • Chronic nasal congestion/runny nose
• • Chronic cough
• • Situs/laterality defects
• • Bronchiectasis
• • Ability to provide informed consent or consent of parent/guardian and ass
• Exclusion Criteria:
• • Recent history of sinus surgery or bloody nose in the past week
• • Age \< 2 years of age
• • Inability to tolerate probe in nose
• • Sinusitis or other respiratory exacerbation currently being treated with antibiotics
• • Admitted to hospital for respiratory exacerbation (inpatient status)
• • Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by the IRB)
• • Any other reason for which the study investigators feel the patient is not a good candidate to complete the testing